Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2016 Net Income-$6.03M-$6.03MderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$5,891,000N/M Operating Cash Flowderived-$2,152,000N/M Free Cash Flowderived-$2,156,000— ended Dec 31, 2017 · filed Mar 1, 2018 · 60 d after period end